TY - JOUR
T1 - Using qualitative research to understand what outcomes matter to patients
T2 - direct and indirect approaches to outcome elicitation
AU - Mathers, Jonathan
AU - Keeley, Thomas
AU - Jones, Laura
AU - Calvert, Melanie
AU - Williamson, Paula R.
AU - Jones, Janet
AU - McMullan, Christel
AU - Wright, Sue
AU - Young, Bridget
PY - 2015/11/16
Y1 - 2015/11/16
N2 - There is a need for patient involvement when selecting trial outcomes, since their priorities may differ from healthcare professionals. Qualitative research can be used to identify outcomes that matter to patients in the development of core outcome sets (COS) and in trial feasibility studies that aim to feed patient perspectives into outcome domain selection for the definitive trial. For example, the COMET database currently includes 24 published (2-3/year) and 33 ongoing COS studies utilising interviews or focus groups with patients, carers and their representatives. However, it is unclear whether direct approaches to eliciting outcomes or indirect approaches focusing on the disease and treatment are most useful in informing trial design and outcome selection.
AB - There is a need for patient involvement when selecting trial outcomes, since their priorities may differ from healthcare professionals. Qualitative research can be used to identify outcomes that matter to patients in the development of core outcome sets (COS) and in trial feasibility studies that aim to feed patient perspectives into outcome domain selection for the definitive trial. For example, the COMET database currently includes 24 published (2-3/year) and 33 ongoing COS studies utilising interviews or focus groups with patients, carers and their representatives. However, it is unclear whether direct approaches to eliciting outcomes or indirect approaches focusing on the disease and treatment are most useful in informing trial design and outcome selection.
U2 - 10.1186/1745-6215-16-S2-O39
DO - 10.1186/1745-6215-16-S2-O39
M3 - Article
SN - 1745-6215
VL - 16
JO - Trials
JF - Trials
IS - Supplement 2
M1 - O39
ER -